Endocrinol Metab.  2010 Jun;25(2):157-158. 10.3803/EnM.2010.25.2.157.

Letter: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)

• Ahn YB

• KMID: 2169024
• DOI: http://doi.org/10.3803/EnM.2010.25.2.157

Abstract

No abstract available.

MeSH Terms

Humans
Octreotide
Peptides, Cyclic
Somatostatin
Octreotide
Peptides, Cyclic
Somatostatin

Reference

1. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J. SMS995B2401 Study Group. A prospective multicentre study to investigate the efficacy safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007. 66:859–868.

2. Kim JY, Jee JH, Yoon CH, Chung YJ, Lee BY, Cho GY, Kim SY, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Efficacy of octreotide LAR in acromegalic patients. J Korean Soc Endocrinol. 2005. 20:344–352.

3. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006. 91:2112–2118.

4. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008. 68:473–480.